



Theratechnologies Announces End of Patient Treatment for Phase III Ibalizumab Trial

October 24, 2016

Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that it has been notified today by its partner, TaiMed Biologics, Inc., that the last patient enrolled in the Phase III study of ibalizumab, in combination with optimized background regimen, for patients infected with multi-drug resistant HIV-1 has completed the treatment phase of the study.